A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future

Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but quite frequently overlap in some of their pathophysiological and clinical characteristics. This has generated the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of chronic obstructive pulmonary disease 2020-01, Vol.15, p.2091-2100
Hauptverfasser: Pérez de Llano, Luis, Miravitlles, Marc, Golpe, Rafael, Alvarez-Gutiérrez, Francisco Javier, Cisneros, Carolina, Almonacid, Carlos, Martinez-Moragon, Eva, Gonzalez-Barcala, Francisco-Javier, Ramos-Barbón, David, Plaza, Vicente, Lopez-Campos, Jose Luis, de-Torres, Juan Pablo, Casanova, Ciro, Garcia Rivero, Juan Luis, Rodriguez Hermosa, Juan, Calle Rubio, Myriam, Soler-Cataluña, Juan Jose, Cosio, Borja G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but quite frequently overlap in some of their pathophysiological and clinical characteristics. This has generated the description of new mixed or overlapping disease phenotypes with no clear biological grounds. In this special article, a group of experts provides their perspective and proposes approaching the treatment of chronic airway disease (CAD) through the identification of a series of therapeutic goals (TG) linked to treatable traits (TT)--understood as clinical, physiological, or biological characteristics that are quantifiable using biomarkers. This therapeutic approach needs validating in a clinical trial with the strategy of identification of TG and treatment according to TT for each patient independently of their prior diagnosis. Keywords: airflow obstruction, biomarker, personalised medicine, COPD asthma overlap
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S263430